ClinicalTrials.gg

Myeloproliferative Disorders clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 667 studies for Myeloproliferative Disorders across more than 10 countries. 110 are recruiting or about to start. 218 of them are mainly about Myeloproliferative Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 10 narrower conditions too, such as Leukemia, Myelogenous, Chronic, BCR-ABL Positive: 2,265 studies, 342 open.

ClinicalTrials.gov finds 2,563 studies for Myeloproliferative Disorders. How that becomes 665 here

This page counts the studies the registry files under Myeloproliferative Disorders, and those it files under no condition that list Myeloproliferative Disordersthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,563Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,574Filed under a narrower condition, counted on its own pageLeukemia, Myelogenous, Chronic, BCR-ABL Positive 794 · Primary Myelofibrosis 306 · Leukemia, Myeloid, Chronic-Phase 142 · Leukemia, Erythroblastic, Acute 133 · Blast Crisis 74 · Polycythemia Vera 74 · 4 more
  3. −324Match it another way7 name it in the title and 317 by a synonym or other text the search reads.
  4. 665The count on this page1 of them list Myeloproliferative Disorders in their own words; the registry filed them under no condition.

Status

Completed
357
Terminated
93
Recruiting
87
Active, not recruiting
47
Status unknown
31
Withdrawn
27

Phase

Phase 2
284
Phase 1
181
Phase 3
65
Early Phase 1
4
Phase 4
4

Where

United States
484
France
78
Italy
68
Canada
58
Germany
54
United Kingdom
44

Who develops what

Add Myeloproliferative Disorders to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 3 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AspirinRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06002490 · PharmaEssentia Japan K.K. · Phase 3 · background · “Low-dose aspirin” · registered Jul 2023
  • NCT04182100 · PharmaEssentia Japan K.K. · Phase 2 · background · “Low-dose aspirin” · registered Nov 2019
Bayer25% of its industry studies11 study
ruxolitinibEarlier only
Evidence
  • NCT04562389 · Karyopharm Therapeutics Inc · Phase 3 · live · background · “Ruxolitinib” · registered Sep 2020
  • NCT02158858 · Constellation Pharmaceuticals · Phase 2 · background · “Ruxolitinib” · registered Jun 2014
  • NCT01787552 · Novartis · Phase 2 · background · “INC424” · registered Feb 2013
Incyte Corporation72% of its industry studiesUS: Incyte Corporation (FDA 2011)EU: Novartis (EMA 2012) + 1 other00 studies
anagrelideEarlier only
Evidence
  • NCT04285086 · PharmaEssentia · Phase 3 · live · comparator · “Anagrelide” · registered Feb 2020
  • NCT03123588 · Incyte Corporation · Phase 2 · comparator · “Anagrelide” · registered Apr 2017
  • NCT02076815 · AOP Orphan Pharmaceuticals AG · Phase 3 · comparator · “Thromboreductin” · registered Feb 2014
Takeda67% of its industry studiesUS: off-patent, 2 generics marketedEU: off-patent, 1 generic authorized00 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Myeloproliferative Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 12 open · Alkylating agents 11 open · Tyrosine kinase inhibitors (TKIs) 11 open · JAK inhibitors 6 open · Calcineurin inhibitors 3 open

Coming up

49studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger. 22 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (7%) take healthy volunteers.

Recruiting studies that take each age, of 87
AgeWomenMen
1019 (22%)19 (22%)
1884 (97%)84 (97%)
3084 (97%)84 (97%)
4081 (93%)81 (93%)
5081 (93%)81 (93%)
6578 (90%)78 (90%)
7576 (87%)76 (87%)
8568 (78%)68 (78%)

Across all 667 studies, recruiting or not: 29% stop at 75 or younger and 16% at 65; 30% take children; <1% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myeloproliferative Disorders studies take

Of 87 phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 68 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 167 mo37–140 · 40 studies——
Phase 1/262 mo30–125 · 22 studies——
Phase 268 mo37–111 · 87 studies—75 mo38–118 · 74 studies
Phase 351 mo37–77 · 20 studies——
Interventional, no phase54 mo20–128 · 26 studies——
Observational41 mo24–62 · 37 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 667. Browse all 667 → or search them.